Decreasing Voriconazole Requirement in a Patient After Extracorporeal Membrane Oxygenation Discontinuation: A Case Report.
Beaumont Hospital, Department of Pharmacy, Royal Oak, MI, USA, 48073.
Children's Hospital Colorado, Aurora, CO, USA, 80023.
Children's Hospital Colorado, Department of Pharmacy, Aurora, CO, USA.
Beaumont Hospital, Department of Infectious Diseases, Royal Oak, MI, USA, 48073.
Oakland University William Beaumont School of Medicine, Rochester, MI, USA, 48309.
- Published Article
Transplant Infectious Disease
Wiley (Blackwell Publishing)
- Publication Date
Dec 14, 2020
Patients receiving extracorporeal membrane oxygenation (ECMO) may display large decreases in drug concentrations due to increases in volume of distribution and drug binding to ECMO circuits, tubing, oxygenator and coating materials. We report a case of a critically-ill male who was 10 months status post deceased donor renal transplant being treated with voriconazole for suspected Aspergillosis. Initially, multiple dose increases, up to 11.3mg/kg/dose, were required while on ECMO therapy to obtain goal voriconazole trough concentrations between 2 - 5.5 mcg/ml. The patient's voriconazole dose requirement subsequently decreased to 7.3 mg/kg/dose after ECMO discontinuation, which represented a 45% reduction in voriconazole dose requirement. Based upon this experience, voriconazole appears to bind to artificial surfaces on ECMO devices. In addition to close monitoring of trough levels, it may be appropriate to empirically reduce the voriconazole dose in patients after ECMO discontinuation. This article is protected by copyright. All rights reserved.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 01/04/2021 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/33316840